Billionaire Bill Gates Has 66% of His Foundation's $44 Billion Portfolio Invested in 3 Phenomenal Stocks
But Gates is extremely generous with his wealth; he's one of the most philanthropic billionaires in the world. He stepped down from his position as CEO of Microsoft in 2000 to focus more on his nonprofit foundation. He and ex-wife Melinda Gates started the Bill & Melinda Gates Foundation that year to advance global healthcare and reduce poverty around the world. Over the last 30 years, the two of them have donated an estimated $47.7 billion of their wealth to their foundation and its predecessor.
The foundation's trust includes a highly concentrated equity portfolio that shows the influence of Gates, as well as longtime friend and former Gates Foundation trustee Warren Buffett. While it holds around $44 billion worth of assets, about two-thirds of that is held in just three stocks. Here's a closer look at Gates' top public investments for his foundation.
Gates owned 45% of Microsoft shares after its initial public offering in 1986. Today he owns less than 1% of the company. A lot of Gates' stock went to the Gates Foundation over the years, including a donation of roughly $5 billion worth of shares in 2022.
That donation brought the Gates Foundation's stake in Microsoft to more than 39 million shares. It's held on to the majority of those shares, with about 28.5 million left in the portfolio as of the end of 2024. Those shares are worth $11.2 billion, as of this writing.
Holding Microsoft over the last two years has been an excellent investment for the Gates Foundation and all its other investors. The stock has climbed more than 60% since the end of 2022, outperforming the S&P 500 (SNPINDEX: ^GSPC).
Microsoft's growth is fueled in large part by its positions in artificial intelligence (AI). The company owns one of the largest public cloud computing platforms, Azure, and its early investments in OpenAI gave it a leg up in creating tools for developers around generative AI.
Management said Azure AI services grew 157% year over year during Microsoft's most recent quarter, contributing 13 percentage points of growth to the cloud platform overall. Importantly, management said it remained capacity constrained, which suggests growth could accelerate in the second half of the year.
Microsoft is also one of the largest enterprise software providers in the world, led by its Microsoft 365 productivity suite, which includes Office, collaboration tools, and cloud storage. It offers its own line of AI-powered chatbots called Copilots to help users get more out of the software using natural language. Its Copilot for GitHub can help developers code more effectively and efficiently.
And Microsoft offers enterprise customers access to Copilot Studio to develop their own Copilots, harnessing their own data. Copilot adoption is helping expand the market for the already ubiquitous software suite while driving higher revenue per license.
Microsoft shares trade for about 26 times forward earnings estimates, as of this writing. While that's a premium to the overall market, it arguably deserves that premium. It's at the forefront of advances in AI in two areas, benefiting from the continued growth in spending on AI software and development. Its massive annual free cash flow ensures it can invest to meet the needs of its customers, while using excess capital to buy back shares and boost earnings per share.
Warren Buffett isn't just a friend of Gates or a former trustee for his foundation -- he's also one of its biggest donors. He's made an annual contribution to the Gates Foundation since 2006, always in the form of Berkshire Hathaway (NYSE: BRK.B) (NYSE: BRK.A) shares.
As of the end of 2024, the Gates Foundation held 19.7 million Class B shares of Berkshire Hathaway. That stake is worth $10.5 billion, as of this writing.
Shares of Berkshire Hathaway have performed extraordinarily well over the last couple of years, and it now stands at a record market value of $1.15 trillion. That's despite Buffett's moves in Berkshire's equity portfolio to trim positions in several notable holdings and pile more of its assets into cash and Treasuries. Had he not sold those stocks, Berkshire would be worth even more.
Berkshire's growth can be attributed to its owned and operated businesses, led by its insurance division. The company's operating earnings increased 27% last year, on top of 21% growth in 2023. Combined with strong performance in Berkshire's equity portfolio, it's pushed the value of the stock higher.
But Buffett's recent actions suggest he thinks the stock might be too expensive right now. The Berkshire board of directors changed the company's share repurchase program in 2018 to allow Buffett to buy back shares whenever he felt they were priced below their intrinsic value. He bought back shares every quarter until the third quarter last year. Shares have consistently traded above a price-to-book-value ratio of 1.5 since then, frequently exceeding 1.6.
As of this writing, Berkshire shares trade for 1.77 times book value. That's a valuation the stock hasn't reached in more than 15 years. While there are some good reasons for Berkshire to trade at a higher ratio to book value right now, considering it's not really using the insurance business for leverage in its equity investments, that price still seems very high.
Investors may be better off with other investments now and waiting for Berkshire's price to come back toward a safer valuation.
Waste Management (NYSE: WM) is a longtime holding for the Gates Foundation trust, and it has steadily added shares over time. It's a boring business that's relatively immune to economic slowdowns. (People will always have trash.) And it has a massive competitive moat that ensures it's not in danger of losing its steady revenue streams anytime soon. It's clear Gates was heavily influenced by Warren Buffett.
The Gates Foundation held 32.2 million shares of Waste Management as of the end of the fourth quarter. Those shares are worth approximately $7.4 billion as of this writing. It's worth noting that the trustees rarely sell shares of the stock, unlike its positions in Microsoft and Berkshire Hathaway. So, the holding could end up becoming a bigger portion of its portfolio in the future.
Waste Management is the largest waste collection and disposal company in the United States. That in and of itself is a great advantage for the business, as it's able to capture high-density routes, making its operations more efficient than smaller companies in its industry.
That scale also gives it the cash flow needed to expand via acquisition, which it's done strategically. Most recently, it acquired medical waste management company Stericycle. The new addition contributes to Waste Management's growth.
Management's 2025 outlook for 16.4% revenue growth includes 10.7 percentage points from acquisitions. Despite the acquisitions, the company sees 17.6% growth in free cash flow this year, giving it the confidence to raise its dividend 10% earlier this year.
But Waste Management's biggest competitive advantage is its dominant landfill ownership. Due to strict regulations, only a tiny handful of competitors can replicate its fully integrated waste hauling business. The industry is practically impenetrable to new competition. As such, Waste Management is well positioned to provide stable returns for investors, year in and year out.
The stock trades for an enterprise value-to-adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio of about 15 times management's 2025 outlook. That's a fair price to pay, especially for those looking for a defensive stock that can withstand the current uncertain macroeconomic environment.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $284,402!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $41,312!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $503,617!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, and there may not be another chance like this anytime soon.*Stock Advisor returns as of March 24, 2025
Adam Levy has positions in Microsoft. The Motley Fool has positions in and recommends Berkshire Hathaway and Microsoft. The Motley Fool recommends Waste Management and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Billionaire Bill Gates Has 66% of His Foundation's $44 Billion Portfolio Invested in 3 Phenomenal Stocks was originally published by The Motley Fool
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
US stock futures steady as investors await payrolls data
(Reuters) -U.S. stock index futures held steady on Thursday as investors awaited the monthly jobs report for insights on the health of the labor market and the Federal Reserve's plans for monetary easing. The S&P 500 and Nasdaq closed at record highs after Wednesday's choppy session, boosted by gains in technology stocks and a trade agreement between the United States and Vietnam that eased concerns about prolonged trade tensions. The blue-chip Dow closed 1.3% below all-time highs touched in December. All eyes are on the nonfarm payrolls report for June, which is scheduled to be released at 8:30 a.m. ET (1230 GMT) - a day ahead of schedule because the U.S. markets are closed on July 4 for Independence Day. Trading volumes are expected to be light, with markets closing early, at 1 p.m. ET on Thursday. The data is expected to show the U.S. labor market slowed further in June, with the unemployment rate expected to have edged up to more than a three-and-a-half-year high of 4.3%, as economic uncertainty stemming from the Trump administration's policies curbed hiring. "Chair (Jerome) Powell, leading the camp for the Fed to keep rates on hold, argues that sticky inflation and a solid labor market mean that the policy rate should be kept mildly restrictive," ING analysts said in a note. "Clearly, any downside surprise in the jobs report would weaken his (Powell's) position and allow the market to push on with pricing a rate cut at the July meeting." Traders are attaching a 25% chance of the U.S. Federal Reserve cutting rates at the July meeting, according to CME Group's Fedwatch tool, up from about 20% a week ago. U.S. stocks dipped briefly on Wednesday after data showed private payrolls fell in June for the first time in more than two years. Other economic data on Thursday includes weekly jobless claims and the S&P Global and ISM services sector activity readings for June. Meanwhile, Republicans in the U.S. House of Representatives advanced President Donald Trump's massive tax-cut and spending bill toward a final yes-or-no vote, appearing to overcome internal party divisions over its cost. The legislation is expected to add $3.4 trillion to the nation's $36.2 trillion in debt over the next decade, according to nonpartisan analysts. By 5:49 a.m. ET (0949 GMT), S&P 500 e-minis were up 4 points, or 0.06%, Nasdaq 100 e-minis climbed 24.25 points, or 0.11%, and Dow e-minis added 30 points, or 0.07%. Shares of chip design software firms Synopsys and Cadence Design Systems climbed 6.7% and 5.9%, respectively, in premarket trading after the U.S. lifted export restrictions on chip design software to China, signaling a thaw in trade tensions between the world's top two economies. Tripadvisor climbed 4.9% after the Wall Street Journal reported activist investor Starboard Value had built a more than 9% stake in the online travel firm. Datadog jumped 10.2% after the cloud security firm was set to replace Juniper Networks on the S&P 500.
Yahoo
19 minutes ago
- Yahoo
Why Amgen Stock Popped by 4% Today
Investors continued to snap up shares following Monday's good news from the company. Analysts were generally positive about the latest development, too. 10 stocks we like better than Amgen › Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development. With that share price rise, Amgen easily beat the S&P 500 index, which slid by 0.1%. That news concerned Amgen's investigational stomach cancer drug, bemarituzumab. The company announced Monday that, in combination with chemotherapy, the treatment met its primary endpoint of of overall survival for the patients tested in a phase 3 clinical trial. It compared favorably to the results of patients only taking a placebo and receiving chemotherapy. The study had an enrollment of 547 patients who suffered from certain types of unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer. Amgen pointed out in its press release on the trial's results that gastric cancer is the fifth-leading cause of cancer-related death in the world, with over 650,000 fatalities. The two immediate analyst reactions to the news were both positive and complimentary. Piper Sandler's David Amsellem reiterated his overweight (i.e., buy) recommendation and $328 per share price target. According to reports, Amsellem said that while there were some concerns with the study, its results were positive, and Amgen could have quite a successful drug on its hands. As cancer is a persistent and tough challenge, any advancement in its treatment is cause for optimism. While Amgen could have provided more details of the study (it pledged to do so in an unspecified presentation in the near future), the rough outlines of bemarituzumab are encouraging. The company might very well be on the cusp of success with the drug. Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $722,181!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $968,402!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool has a disclosure policy. Why Amgen Stock Popped by 4% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Global Growth Companies With High Insider Ownership In July 2025
In the wake of record highs for the S&P 500 and Nasdaq Composite, driven by easing geopolitical tensions and promising trade developments, global markets are reflecting a cautiously optimistic sentiment despite inflationary pressures. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those who know the business best, aligning well with current market conditions that favor stability and strategic foresight. Name Insider Ownership Earnings Growth Zhejiang Leapmotor Technology (SEHK:9863) 15.6% 60.5% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 23.5% Samyang Foods (KOSE:A003230) 11.7% 24.8% Pharma Mar (BME:PHM) 11.8% 44.9% Marinomed Biotech (WBAG:MARI) 29.7% 20.2% Laopu Gold (SEHK:6181) 35.5% 41.2% KebNi (OM:KEBNI B) 38.3% 94.5% Fulin Precision (SZSE:300432) 13.6% 43.7% Elliptic Laboratories (OB:ELABS) 24.4% 79% Bergen Carbon Solutions (OB:BCS) 12% 63.2% Click here to see the full list of 835 stocks from our Fast Growing Global Companies With High Insider Ownership screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BrightGene Bio-Medical Technology Co., Ltd. is a pharmaceutical company involved in the research, development, manufacture, and commercialization of pharmaceutical products in China with a market cap of CN¥22.34 billion. Operations: BrightGene Bio-Medical Technology Co., Ltd. generates revenue through its pharmaceutical product research, development, manufacturing, and commercialization activities in China. Insider Ownership: 26.9% Earnings Growth Forecast: 32.1% p.a. BrightGene Bio-Medical Technology is experiencing significant earnings growth, forecasted at 32.1% annually, outpacing the Chinese market. Despite high volatility in its share price and challenges in covering interest payments with earnings, it remains financially promising due to robust revenue growth projections of 17.4%. Recent advancements include promising Phase 2 results for its dual agonist BGM0504 and novel amylin analog BGM1812, highlighting potential in weight management and metabolic disease treatment. Get an in-depth perspective on BrightGene Bio-Medical Technology's performance by reading our analyst estimates report here. According our valuation report, there's an indication that BrightGene Bio-Medical Technology's share price might be on the expensive side. Simply Wall St Growth Rating: ★★★★★☆ Overview: Xi'an Bright Laser Technologies Co., Ltd. provides metal additive manufacturing and repairing solutions in China, with a market cap of CN¥15.22 billion. Operations: Xi'an Bright Laser Technologies Co., Ltd. generates revenue through its metal additive manufacturing and repairing solutions within the People's Republic of China. Insider Ownership: 24.8% Earnings Growth Forecast: 54.2% p.a. Xi'an Bright Laser Technologies is positioned for rapid growth, with revenue expected to increase 36.7% annually, surpassing the broader Chinese market. Despite a volatile share price and declining profit margins from 11.3% to 6.6%, earnings are projected to grow significantly at 54.2% per year, highlighting strong potential in the laser technology sector. Recent financials show first-quarter sales of CNY 227 million but a net loss of CNY 14.95 million compared to last year's profit, indicating challenges alongside growth prospects. Navigate through the intricacies of Xi'an Bright Laser TechnologiesLtd with our comprehensive analyst estimates report here. The valuation report we've compiled suggests that Xi'an Bright Laser TechnologiesLtd's current price could be inflated. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥12.12 billion. Operations: The company generates revenue through its activities in research, production, and marketing of Chinese medicinal products within China and on an international scale. Insider Ownership: 23.1% Earnings Growth Forecast: 18.9% p.a. Zhejiang Jolly Pharmaceutical showcases promising growth potential with revenue forecasted to rise over 20% annually, outpacing the Chinese market. Recent earnings reveal a net income increase to CNY 181.15 million, reflecting robust performance despite dividends not being fully covered by free cash flows. Trading at a significant discount to its estimated fair value and expected high return on equity further enhance its investment appeal, though insider trading activity remains minimal in recent months. Click here and access our complete growth analysis report to understand the dynamics of Zhejiang Jolly PharmaceuticalLTD. The valuation report we've compiled suggests that Zhejiang Jolly PharmaceuticalLTD's current price could be quite moderate. Click through to start exploring the rest of the 832 Fast Growing Global Companies With High Insider Ownership now. Want To Explore Some Alternatives? AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SHSE:688166 SHSE:688333 and SZSE:300181. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data